Lexaria Bioscience Corp. announced on November 14, 2024, that it has engaged a contract research organization to perform the world's first-ever fluorescently tagged DehydraTECH-semaglutide (FTS) rodent biodistribution study.
This study aims to track the distribution of DehydraTECH GLP-1 molecules once they enter the body. Understanding drug distribution can provide vital clues regarding a drug's ability to bind with targeted receptor cells and avoid concentrations that might foster adverse side effects.
The insights gained from this biodistribution study are expected to enhance future communications between Lexaria and prospective industry partners, supporting the understanding of DehydraTECH's mechanism of action and potential benefits.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.